May 24, 2007 General News

ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences

SAN DIEGO–(BUSINESS WIRE)–May 24, 2007–ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences:

--  The Bank of America 2007 Health Care Conference on Thursday,
        May 31, 2007, at 9:20 a.m. Pacific Time at the Four Seasons
        Hotel in Las Vegas.

    --  The Sixth Annual Needham & Company Biotechnology and Medical
        Technology Conference on Wednesday, June 13, 2007, at 8:30
        a.m. Eastern Time at The New York Palace Hotel in New York
        City.

    --  The Jefferies Healthcare Conference on Wednesday, June 27,
        2007, at 2:00 p.m. Eastern Time at the Mandarin Oriental Hotel
        in New York City.

Live webcasts of these presentations will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for two weeks following the presentation.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five mid-to-late stage clinical programs as well as a portfolio of preclinical and discovery assets, directed at diseases with large unmet medical needs, including schizophrenia, Parkinson’s disease psychosis, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA’s product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA’s corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.

CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and
Chief Financial Officer
858-558-2871

Investor Contact

Media Contact